USA Daily Letter
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

USA Daily Letter

Politics

Pro-life group urges Senate to press RFK Jr on abortion pill safety, demand safeguards return

by September 4, 2025
September 4, 2025
Pro-life group urges Senate to press RFK Jr on abortion pill safety, demand safeguards return

The Restoration of America Foundation (ROAF) is calling on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at Thursday’s 10 a.m. hearing, demanding answers about the removal of safety protocols for the abortion pill mifepristone.

In a letter provided exclusively to Fox News Digital, ROAF argues the rollback leaves women more vulnerable and shifts costs to taxpayers.

ROAF argues that the Biden-era rollback of Risk Evaluation and Mitigation Strategy (REMS) requirements, safeguards in place for more than two decades, endangers women by allowing abortion pills to be prescribed via telehealth and delivered through the mail.

‘The removal of key Risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone has eliminated essential safeguards that protected women’s health for over two decades,’ said Doug Truax, founder and CEO of the Restoration of America Foundation. ‘We urge the Senate to demand clear answers about why these safety protocols were removed and when they will be reinstated.’

The Food and Drug Administration originally required mifepristone to be dispensed in person to ensure women were screened for potential complications such as ectopic pregnancy. That changed under the Biden administration, when telehealth prescribing and mail-order delivery were permitted for the first time.

Truax warned that ‘allowing these powerful drugs to be ordered online and sent through the mail without proper medical screening puts women at serious risk.’ He added, ‘Women deserve to know about potential complications and have immediate access to emergency care if needed.’

‘As previously mentioned, Secretary Kennedy asked Commissioner Makary to review the latest data on mifepristone,’ said HHS spokeswoman Emily G. Hilliard to Fox News Digital. ‘Commissioner Makary will ensure gold standard science is used while incorporating practical, common-sense considerations to its regulatory processes.’

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Trump family’s American Bitcoin makes stock market debut
next post
Trump health agenda sparks revolt: 3 West Coast governors form vaccine alliance

You may also like

Trump trashes Nadler on heels of Dem’s House...

RFK Jr and top Dem clash during heated...

House Oversight Committee releases thousands of Epstein documents

Trump admin scores legal win in $16B climate...

Hegseth vows to rebuild military deterrence so enemies...

Loyal Ex-Biden aide says fateful debate against Trump...

Trump’s tariffs force China to feel the heat

RFK Jr. defends firing spree at CDC, vows...

Top Biden officials questioned and criticized how his...

List reveals items FBI seized from John Bolton’s...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Vice President JD Vance teases 2028 bid, says it won’t be ‘given’...

    • DAVID MARCUS: The Department of War marks the end of America as the world’s policeman

    • Top Biden officials questioned and criticized how his team issued pardons, used autopen: report

    • Trump caps week with bold military moves from Pentagon name change to cartel crackdown

    • MIKE DAVIS: Impeachment time for Trump-hating renegade Judge Boasberg

    Categories

    • Business (10)
    • Investing (60)
    • Politics (68)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: usadailyletter.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 usadailyletter.com | All Rights Reserved


    Back To Top